Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Jul 15;130(14):2538-2551.
doi: 10.1002/cncr.35275. Epub 2024 Mar 23.

High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT

Luke J Peppone  1   2 , Amber S Kleckner  3 , Chunkit Fung  4 , J Edward Puzas  2 , Jennifer E Reschke  1 , Eva Culakova  1 , Julia Inglis  5 , Charles Kamen  1 , Jonathan W Friedberg  4 , Michelle Janelsins  1 , Karen Mustian  1 , Charles E Heckler  1 , Supriya Mohile  4
Affiliations
Clinical Trial

High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT

Luke J Peppone et al. Cancer. .

Abstract

Background: Androgen deprivation therapy (ADT) inhibits prostate cancer growth. However, ADT causes loss of bone mineral density (BMD) and an increase in fracture risk; effective interventions for ADT-induced bone loss are limited.

Methods: A phase 2 randomized controlled trial investigated the feasibility, safety, and preliminary efficacy of high-dose weekly vitamin D (HDVD, 50,000 IU/week) versus placebo for 24 weeks in patients with prostate cancer receiving ADT, with all subjects receiving 600 IU/day vitamin D and 1000 mg/day calcium. Participants were ≥60 years (mean years, 67.7), had a serum 25-hydroxyvitamin D level <32 ng/mL, and initiated ADT within the previous 6 months. At baseline and after intervention, dual-energy x-ray absorptiometry was used to assess BMD, and levels of bone cell, bone formation, and resorption were measured.

Results: The HDVD group (N = 29) lost 1.5% BMD at the total hip vs. 4.1% for the low-dose group (N = 30; p = .03) and 1.7% BMD at the femoral neck vs. 4.4% in the low-dose group (p = .06). Stratified analyses showed that, for those with baseline 25-hydroxyvitamin D level <27 ng/mL, the HDVD group lost 2.3% BMD at the total hip vs 7.1% for the low-dose group (p < .01). Those in the HDVD arm showed significant changes in parathyroid hormone (p < .01), osteoprotegerin (p < 0.01), N-terminal telopeptide of type 1 collagen (p < 0.01) and C-terminal telopeptide of type 1 collagen (p < 0.01). No difference in adverse events or toxicity was noted between the groups.

Conclusions: HDVD supplementation significantly reduced hip and femoral neck BMD loss, especially for patients with low baseline serum 25-hydroxyvitamin D levels, although demonstrating safety and feasibility in prostate cancer patients on ADT.

Keywords: adverse effects; hormonal therapy; osteoporosis; prostatic neoplasms; vitamin D; vitamins.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST STATEMENT

The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or competitors.

Figures

FIGURE 1
FIGURE 1
CONSORT diagram.
FIGURE 2
FIGURE 2
Change in serum 25(OH)D levels. 25(OH)D indicates 25-hydroxyvitamin D.
FIGURE 3
FIGURE 3
Change in serum calcium.
See this image and copyright information in PMC

References

    1. Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2007; 177(1 ):17–24. doi: 10.1016/j.juro.2006.08.089 - DOI - PubMed
    1. Mohile SG, Lachs M, Dale W. Management of prostate cancer in the older man. Semin Oncol. 2008;35(6):597–617. S0093-7754(08)00186-3 [pii]. doi: 10.1053/j.seminoncol.2008.08.003 - DOI - PubMed
    1. Mohile SG, Mustian K, Bylow K, Hall W, Dale W. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol. 2009;70(3):235–255. S1040-8428(08)00216-3 [pii], doi: 10.1016/j.critrevonc.2008.09.004 - DOI - PMC - PubMed
    1. Mohile SG, Petrylak DP. Management of asymptomatic rise in prostatic-specific antigen in patients with prostate cancer. Curr Oncol Rep. 2006;8(3):213–220. doi: 10.1007/s11912-006-0022-8 - DOI - PubMed
    1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004:22(11):2141–2149. JCO.2004.10.062 [pii]. doi: 10.1200/JCO.2004.10.062 - DOI - PMC - PubMed

Publication types

MeSH terms